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Background
There is evidence for neurodevelopmental aberrations in
both schizophrenia and bipolar disorder. We have studied
the genes for synaptosomal associated protein of 25 kilo-
daltons (SNAP-25) and the brain derived neurotrophic
factor (BDNF), that are known to be involved in normal
brain development. SNAP-25 expression is associated
with regions of high synaptic plasticity and is required for
axonal elongation. A strain of mouse designated colo-
boma possessing a 2 cM deletion encompassing the Snap-
25 gene exhibits hyperactivity, delayed development, and
abnormalities in dopaminergic, serotonergic, and gluta-
matergic transmission. Additionally, several studies have
suggested a direct involvement of SNAP-25 in schizophre-
nia etiology based upon altered levels of brain and CSF
expression. Furthermore, our group (Wong et al., 2003)
have observed SNAP-25 expression to be significantly
altered in rats treated with the antipsychotic medication
haloperidol, versus controls. We examined transmission
of alleles at three single nucleotide polymorphisms in the
SNAP-25 gene in more than 100 schizophrenia triad fam-
ilies and found evidence of a haplotype related to the dis-
ease (Klempan et al., 2002).
Material and Methods
We then went further to examine SNAP-25 in antipsy-
chotic drug response, investigating a sample of 61 schizo-
phrenia patients who had undergone an antipsychotic
drug clinical trial.
Results
ANOVA-based analysis of SNAP-25 genotypes against
mean change in the PANSS scores (14 week) for this sam-
ple is significant for two of the three genetic variants
(DdeI: *F = 0.147, p = 0.703; MnlI: *F = 5.586, p =
0.008;TaiI: *F = 5.525, p = 0.008).
Discussion
It may be that SNAP-25 gene variation alters the course of
neurodevelopment in individuals who go on to have
schizophrenia, or it may influence the synaptogenic role
that SNAP-25 plays in adult humans. Another gene of
neuro-developmental interest is the BDNF. We have
shown that BDNF plays an important role in risk for bipo-
lar mood disorder (Neves-Pereira et al., 2002), child onset
depression (Strauss et al., 2002) and possibly in schizo-
phrenia (Muglia et al., 2003). We are currently dissecting
the phenotype in these disorders to test whether BDNF is
involved more specifically in mood, psychotic symptoms,
early onset, cognition, or drug response. Overall, the
genetic prediction of these major psychiatric disorders is
moving closer to clinical application.
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